S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Forecast, Price & News

$3.26
-0.08 (-2.40%)
(As of 09/26/2023 ET)
Compare
Today's Range
$3.25
$3.40
50-Day Range
$3.26
$3.86
52-Week Range
$2.90
$6.45
Volume
15,071 shs
Average Volume
46,708 shs
Market Capitalization
$101.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Anixa Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.1% Upside
$10.50 Price Target
Short Interest
Healthy
2.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Anixa Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$42,126 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.32) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

310th out of 964 stocks

Pharmaceutical Preparations Industry

124th out of 438 stocks


ANIX stock logo

About Anixa Biosciences (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Price History

ANIX Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Anixa Biosciences Establishes Cancer Business Advisory Board
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
Anixa Biosciences (ANIX) Receives a Buy from H.C. Wainwright
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
See More Headlines
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Company Calendar

Last Earnings
8/31/2021
Today
9/27/2023
Fiscal Year End
10/31/2023
Next Earnings (Estimated)
1/03/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIX
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+222.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,600,000.00
Pretax Margin
-5,113.33%

Debt

Sales & Book Value

Annual Sales
$510,000.00
Book Value
$0.92 per share

Miscellaneous

Free Float
24,732,000
Market Cap
$101.29 million
Optionable
Not Optionable
Beta
0.94
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Amit Kumar Ph.D. (Age 59)
    Chairman & CEO
    Comp: $1.07M
  • Mr. Michael J. Catelani CPA (Age 56)
    MBA, Pres, COO, CFO & Corp. Sec.
    Comp: $550.96k
  • Mr. John Roop (Age 73)
    Sr. VP of Engineering
  • Dr. Thomas Schlumpberger Ph.D. (Age 57)
    Exec. VP of Diagnostics
  • Dr. Pamela D. Garzone Ph.D. (Age 68)
    Chief Devel. Officer & Chair Breast Cancer Clinical Advisory Board













ANIX Stock - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings
or view top-rated stocks.

What is Anixa Biosciences' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year target prices for Anixa Biosciences' shares. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 222.1% from the stock's current price.
View analysts price targets for ANIX
or view top-rated stocks among Wall Street analysts.

How have ANIX shares performed in 2023?

Anixa Biosciences' stock was trading at $4.25 at the beginning of the year. Since then, ANIX shares have decreased by 23.3% and is now trading at $3.26.
View the best growth stocks for 2023 here
.

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 3rd 2024.
View our ANIX earnings forecast
.

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) released its quarterly earnings results on Tuesday, August, 31st. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06.

What other stocks do shareholders of Anixa Biosciences own?
What is Anixa Biosciences' stock symbol?

Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX."

Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.98%), BlackRock Inc. (0.81%), Renaissance Technologies LLC (0.19%), Northern Trust Corp (0.17%), JPMorgan Chase & Co. (0.09%) and Tyler Stone Wealth Management (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends
.

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anixa Biosciences' stock price today?

One share of ANIX stock can currently be purchased for approximately $3.26.

How much money does Anixa Biosciences make?

Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $101.29 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Anixa Biosciences?

Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974.

This page (NASDAQ:ANIX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -